Vir Biotechnology (VIR) Notes Payables (2019)

Vir Biotechnology (VIR) reported Notes Payables of $12.4 million for Q4 2019.

Vir Biotechnology (VIR) Notes Payables (2019) Analysis & Trends

Vir Biotechnology (VIR) has 1 years of Notes Payables data on file, last reported at $12.4 million in Q4 2019.

For the quarter ending Q4 2019, Notes Payables changed N/A year-over-year to $12.4 million; the trailing twelve-month figure through Dec 2019 stood at $12.4 million (changed N/A YoY), and the FY2019 full-year result was $12.4 million, changed N/A from the prior year.
Notes Payables was little changed at $12.4 million in Q4 2019.
In the past five years, Notes Payables ranged from a high of $12.4 million in Q4 2019 to a low of $12.4 million in Q4 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Vir Biotechnology	1.38 Bn	1.38 Bn	-

Download Data

Date	Value
Dec 31, 2019	12.45 Mn